文献速递流行病学与生物统计真实世界研究与卫生经济

澳大利亚基于家族史的结直肠癌筛查:不同参与情景的成本、收益与危害建模研究

Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
PubMed 文献 · PLoS Med · 2018-08-16

该研究基于澳大利亚结直肠癌家族登记库2480名参与者,按家族史分为平均、中度增加和潜在高风险三类,评估其筛查实践与指南的差距,并用微观模拟比较70%和100%参与率情景与当前水平的临床结局和成本。结果显示各风险类别筛查率均低(64%-56%未筛查),提高筛查可显著降低死亡率,且具成本效益。

要点

  • 各家族史风险类别筛查参与率均低,64%-56%报告未筛查。
  • 平均风险者18%存在过度筛查,最高风险类别仅37%按指南筛查。
  • 提高筛查至70%可大幅降低死亡率,且各风险类别均具成本效益。

核心结论

  • 投资公共卫生策略以提高适当结直肠癌筛查的依从性可挽救生命并具有高性价比。

研究设计与样本

  • 基于澳大利亚结直肠癌家族登记库2480名参与者,按家族史分为平均、中度增加和潜在高风险三类,评估筛查实践。
  • 开发微观模拟模型,比较70%和100%参与率情景与当前基线水平的临床结局和成本。

主要发现

  • 各家族史风险类别筛查参与率均低,64%-56%报告未筛查。
  • 平均风险参与者中18%报告过度筛查,最高风险类别中37%按指南筛查。
  • 较高筛查水平可显著降低所有风险类别的结直肠癌死亡率(70%情景较基线每10万人减少95至305例死亡)。

关键数值与推荐

  • 平均风险者完全实施国家肠癌筛查计划是最具成本效益的预防结直肠癌死亡策略(每质量调整生命年13000-16000澳元)。
  • 中度增加风险者更高依从推荐筛查也具有高成本效益(每质量调整生命年19000-24000澳元)。

临床怎么用

  • 临床应依据家族史风险分层,提高对推荐结直肠癌筛查的依从性,避免平均风险者过度筛查。

局限性

  • 成本效果分析从第三方支付者视角进行,未包括间接成本,导致成本效果比高估。
  • 结直肠癌自然史模型未包括息肉停留时间,而该时间决定癌变速率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Australian National Bowel Cancer Screening Programme (NBCSP) was introduced in 2006. When fully implemented, the programme will invite people aged 50 to 74 to complete an immunochemical faecal occult blood test (iFOBT) every 2 years. METHODS AND FINDINGS: To investigate colorectal cancer (CRC) screening occurring outside of the NBCSP, we classified participants (n = 2,480) in the Australasian Colorectal Cancer Family Registry (ACCFR) into 3 risk categories (average, moderately increased, and potentially high) based on CRC family history and assessed their screening practices according to national guidelines. We developed a microsimulation to compare hypothetical screening scenarios (70% and 100% uptake) to current participation levels (baseline) and evaluated clinical outcomes and cost for each risk category. The 2 main limitations of this study are as follows: first, the fact that our cost-effectiveness analysis was performed from a third-party payer perspective, which does not include indirect costs and results in overestimated cost-effectiveness ratios, and second, that our natural history model of CRC does not include polyp sojourn time, which determines the rate of cancerous transformation. Screening uptake was low across all family history risk categories (64%-56% reported no screening). For participants at average risk, 18% reported overscreening, while 37% of those in the highest risk categories screened according to guidelines. Higher screening levels would substantially reduce CRC mortality across all risk categories (95 to 305 fewer deaths per 100,000 persons in the 70% scenario versus baseline). For those at average risk, a fully implemented NBCSP represented the most cost-effective approach to prevent CRC deaths (AUS$13,000-16,000 per quality-adjusted life year [QALY]). For those at moderately increased risk, higher adherence to recommended screening was also highly cost-effective (AUS$19,000-24,000 per QALY). CONCLUSION: Investing in public health strategies to increase adherence to appropriate CRC screening will save lives and deliver high value for money.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Dillon M, Flander L, Buchanan DD, et al. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios. PLoS Med. 2018. PMID: 30114221. doi:10.1371/journal.pmed.1002630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。